相关临床试验
426
134 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1882
进行中（未招募）
115
27.0%
已完成
206
48.4%
Enrolling By Invitation
2
0.5%
尚未招募
17
4.0%
招募中
51
12.0%
暂停
1
0.2%
终止
9
2.1%
Unknown
11
2.6%
撤回
13
3.0%
暂无批准数据
- ResoTher Pharma reported top-line Phase 2a results showing RTP-026 produced an 8 percentage point median LVEF improvement at Day 90 in both dose groups versus 2.5 points for placebo. - The randomized, double-blind, placebo-controlled study enrolled 66 severe STEMI patients who received three intravenous infusions of 25 or 75 µg/kg RTP-026 within 24 hours after PCI. - RTP-026 was safe and well tolerated, with no deaths, no withdrawals due to adverse events, and serious adverse events in three active-treatment patients attributed to underlying disease. - The readout fulfilled a key condition precedent for Hunter Capital RTO 1's proposed reverse acquisition of ResoTher, which still requires at least SEK 65 million in additional financing.
- A UK cohort study of 28,720 people with type 2 diabetes found that 39% experienced at least one significant health event over a median 6.8 years of follow-up. - Women were more likely to develop mental health conditions post-diagnosis (8.1% vs 5.3%), while men showed higher rates of cardiovascular disease/end-stage renal disease (8.4% vs 5.3%) and hypertension. - Both sexes with a mental health condition following type 2 diabetes experienced premature mortality, with men dying on average 9 years younger than women in the same trajectory. - The authors call for routine mental health screening in diabetes care, particularly for younger women, and earlier cardio-renal monitoring and engagement strategies for men.
- A first-of-its-kind study from King's College London linked coordinated changes in circulating B and T cells to survival outcomes in melanoma patients receiving immunotherapy. - Patients whose B and T cells showed renewed activation and expansion within the first six weeks of treatment had better outcomes, including improved survival. - Patients with immature or poorly functioning B cells, or weaker pre-treatment anti-cancer responses, had poorer survival, while certain T cell subtypes were linked to side effects. - The findings, based on 24 patients and 25 healthy volunteers using mass cytometry, point toward less invasive blood-based biomarkers to guide melanoma treatment decisions.
- A novel non-invasive oral brush biopsy test (qMIDSV3) demonstrated 95.7% sensitivity and 95.1% specificity for detecting oral squamous cell carcinoma in a large diagnostic case-control study of 545 patients. - The test can deliver results within one hour and could spare over 90% of patients with low-risk oral potentially malignant disorders from unnecessary invasive scalpel biopsies. - Researchers were surprised that the brush swab test performed comparably to a microbiopsy, suggesting the four-gene molecular signature is robust enough for superficial cell sampling. - Queen Mary University of London is actively seeking a commercial partner, and the inexpensive test could reach clinical use within two years.
- A new Lancet study reports zero cervical cancer deaths among women aged 20–24 in England who received the HPV vaccine at ages 12–13, compared to an expected 23.1 deaths based on historical rates. - Among women offered catch-up vaccination up to age 18, cervical cancer mortality fell by 80% in the 20–24 age group (2015–2019) and 69% in the 25–29 age group (2020–2024). - Researchers from Queen Mary University of London analyzed mortality data from 2001–2024, providing the first population-level evidence linking HPV vaccination programs to reduced cervical cancer deaths. - Experts caution that expanded screening and herd immunity may also contribute, and longer-term follow-up is needed as vaccinated cohorts age into higher-risk brackets.
- Barts Health NHS Trust remained the UK's top recruiter to commercial drug trials for the seventh year running, enrolling 538 participants across 165 commercial trials in 2025/26. - Over 20,000 patients took part in research during 2025/26, with total research income reaching a record £90 million, including £20 million from commercial trials. - The Trust achieved 11 European or worldwide 'firsts' in patient recruitment and set up 57% of new studies within the national 90-day target. - Research-active organisations deliver better outcomes, giving patients earlier access to new treatments and technologies, according to R&D director Dr Jenny Rivers.
- The world's largest genetic study of blood proteins, involving over 78,000 participants across 38 cohorts, has been published in Cell, revealing new insights into disease mechanisms and drug development opportunities. - Researchers identified evidence that TYK2 inhibitors, currently used for psoriasis, could potentially be repurposed for treating rheumatoid arthritis through multi-layered biomedical data analysis. - A complementary Nature Genetics study analyzing 1,400 volunteers from underrepresented British Bangladeshi and Pakistani communities identified over 1,200 genetic associations with blood protein levels, more than half previously unreported. - The combined findings demonstrate that integrating large-scale proteogenomic data with clinical knowledge can accelerate drug target discovery, drug repurposing, and precision medicine approaches.
- The National Institute for Health and Care Research has launched the UK's first Parkinson's Disease Translational Research Collaboration, bringing together 17 centers of excellence to accelerate treatment and diagnostic development. - The collaboration addresses critical gaps in experimental medicine and early clinical trials for Parkinson's disease, which affects over 166,000 people in the UK. - Led by Professor Oliver Bandmann at Sheffield Teaching Hospitals, the initiative aims to bridge the gap between laboratory discoveries and patient benefits through coordinated translational research. - The PD-TRC represents the eighth NIHR Translational Research Collaboration and will foster partnerships between academia, NHS services, industry, and patient organizations to reduce research inequalities across the UK.
- The phase II DISCUS trial demonstrated that three cycles of chemotherapy followed by avelumab maintenance therapy achieved equivalent survival outcomes to six cycles in 267 patients with advanced bladder cancer. - Patients receiving the reduced three-cycle regimen reported maintained quality of life and experienced fewer severe side effects compared to those receiving six cycles of chemotherapy. - NHS guidelines have been updated to offer eligible patients a choice between three and six chemotherapy cycles followed by avelumab maintenance, potentially benefiting hundreds of patients annually.
- Researchers at Queen Mary University of London have developed the first non-integrase strand-transfer inhibitor (INSTI) single tablet HIV treatment, combining doravirine with islatravir, addressing growing concerns about INSTI resistance in resource-limited settings. - The landmark phase 3 trial published in The Lancet demonstrates that the once-daily doravirine/islatravir combination shows similar efficacy and safety to current integrase inhibitor treatments. - The study recruited higher-than-usual numbers of women, older people, and racially minoritized adults, addressing chronic under-representation in HIV treatment trials. - Islatravir has long-acting potential and is being evaluated as the first weekly tablet for HIV treatment, representing a significant advancement toward more convenient dosing regimens.
